Factors affecting crystallization of hydrates

Journal of Pharmacy and Pharmacology

Volumn 62, Issue 11, 2010, Pages 1534-1546

  Tian, Fang ^a   Qu, Haiyan ^a,b   Zimmermann, Anne ^c   Munk, Tommy ^a   Jørgensen, Anna C ^d   Rantanen, Jukka ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c NEUROSEARCH A S   (Denmark)

^d Ferrosan AS   (Denmark)

Author keywords

crystallization; hydrate; kinetics; salt; thermodynamics

Indexed keywords

INORGANIC SALT;

COOLING; CRYSTAL STRUCTURE; CRYSTALLIZATION; DISSOLUTION; DRUG BIOAVAILABILITY; DRUG FORMULATION; HYDRATION; KINETICS; REVIEW; THERMODYNAMICS;

CHEMISTRY, PHARMACEUTICAL; CRYSTALLIZATION; PHARMACEUTICAL PREPARATIONS; SALTS; SOLUBILITY; WATER;

EID: 78649671797     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2010.01186.x     Document Type: Review

References (98)

1. Griesser UJ,. The importance of solvates. In:, Hilfiker R, ed. Polymorphism in the Pharmaceutical Industry. Weinheim: Wiley-VCH Verlag GmbH & Co., 2006: 211-257.
2. Morris KR, Rodríguez-Hornedo N,. Hydrates. In:, Swarbrick J, Boylan JC, eds. Encyclopaedia of Pharmaceutical Technology. New York: Marcel Dekker, 1993: 393-440.
3. Morris KR,. Structural aspects of hydrates and solvates. In:, Brittain HG, ed. Polymorphism in Pharmaceutical Solids. New York: Marcel Dekker, 1999: 125-181.
4. Stephenson GA, et al. Formation of isomorphic desolvates: creating a molecular vacuum. J Pharm Sci 1998; 87: 536-542.
5. Pfeiffer RR, et al. Crystal pseudopolymorphism of cephaloglycin and cephalexin. J Pharm Sci 1970; 59: 1809-1812.
6. Chen LR, et al. Solid-state behavior of cromolyn sodium hydrates. J Pharm Sci 1999; 88: 1191-1200.
7. Kawakami K, et al. Effect of salt type on hygroscopicity of a new cephalosporin S-3578. Pharm Res 2005; 22: 1365-1373.
8. Vogt FG, et al. A study of variable hydration states in topotecan hydrochloride. J Pharm Biomed Anal 2006; 40: 1080-1088.
9. Zimmermann A, et al. Structural characterisation and dehydration behaviour of siramesine hydrochloride. J Pharm Sci 2009; 98: 3596-3607.
10. Sun C, et al. Theophylline monohydrate. Acta Crystallogr Sect E Struct Rep Online 2002; 58: o368-o370.
11. Gossman WL, et al. Three hydrates of the bisphosphonate risedronate, consisting of one molecular and two ionic structures. Acta Crystallogr C 2003; 59: m33-m36.
12. Khankari RL, et al. Physical characterization of nedocromil sodium hydrates. J Pharm Sci 2000; 87: 1052-1061.
13. Cabri W, et al. Cefdinir: a comparative study of anhydrous vs. monohydrate form: microstructure and tabletting behavior. Eur J Pharm Biopharm 2006; 64: 212-221.
14. Yoshiaki K, et al. Characterization of polymorphs of tranilast anhydrate and tranilast monohydrate when crystallized by two solvent change spherical crystallization techniques. J Pharm Sci 1991; 80: 472-478.
15. Allen PV, et al. Physical characterization of erythromycin: anhydrate, monohydrate, and dihydrate crystalline solids. J Pharm Sci 1978; 67: 1087-1093.
16. Henwood SQ, et al. Characterization of the solubility and dissolution properties of several new rifampicin polymorphs, solvates, and hydrates. Drug Dev Ind Pharm 2001; 27: 1017-1030.
17. Aaltonen J, et al. In-situ measurement of solvent mediated phase transformations during dissolution testing. J Pharm Sci 2006; 95: 2730-2737.
18. Savolainen M, et al. Better understanding of dissolution behaviour of amorphous drugs by in situ solid-state analysis using Raman spectroscopy. Eur J Pharm Biopharm 2009; 71: 71-79.
19. Alonzo DE, et al. Understanding the behavior of amorphous pharmaceutical systems during dissolution. Pharm Res 2010; 27: 608-618.
20. Greco K, et al. Design and characterization of a laminar flow-through dissolution apparatus: comparison of hydrodynamic conditions to those of common dissolution techniques. Pharm Dev Technol 2010; doi:10.3109/10837450903499341. [epub ahead of print.
21. Lehto P, et al. Solvent-mediated solid phase transformations of carbamazepine: effects of simulated intestinal fluid and fasted state simulated intestinal fluid. J Pharm Sci 2009; 98: 985-996.
22. Airaksinen S, et al. Effects of excipients on hydrate formation in wet masses containing theophylline. J Pharm Sci 2003; 92: 516-528.
23. Tian F, et al. Influence of polymorphic form, morphology and excipient interactions on the dissolution of carbamazepine compacts. J Pharm Sci 2007; 96: 584-594.
24. Tian F, et al. The influence of various excipients on the conversion kinetics of carbamazepine polymorphs in aqueous suspension. J Pharm Pharmacol 2006; 59: 193-201.
25. Salameh AK, Taylor LS,. Physical stability of crystal hydrates and their anhydrates in the presence of excipients. J Pharm Sci 2005; 95: 446-461.
26. Qu H, et al. Additive effects on the solvent-mediated anhydrate/hydrate phase transformation in a mixed solvent. Cryst Growth Des 2007; 7: 724-729.
27. Rasenack N, Müller BW,. Ibuprofen crystals with optimized properties. Int J Pharm 2002; 245: 9-24.
28. Wong MWY, Mitchell AG,. Physicochemical characterization of a phase change produced during the wet granulation of chlorpromazine hydrochloride and its effects on tableting. Int J Pharm 1992; 88: 261-273.
29. Huttenrauch R, Fricke S,. Piroxicam-pseudopolymorphism and the ability to agglomerate. Pharmazie 1989; 44: 726-727. [in German]
30. Sun C, Grant DJW,. Improved tableting properties of p-hydroxybenzoic acid by water of crystallization: a molecular insight. Pharm Res 2004; 21: 382-386.
31. Byrn SR, et al., eds. Solid State Chemistry of Drugs, 2nd edn. West Lafayette, IN: SSCI Inc., 1999.
32. Haleblian JK,. Characterization of habits and crystalline modification of solids and their pharmaceutical applications. J Pharm Sci 1975; 64: 1269-1288.
33. Vippagunta SR, et al. Crystalline solids. Adv Drug Deliv Rev 2001; 48: 3-26.
34. Infantes L, et al. Organic crystal hydrates: what are the important factors for the formation. Cryst Eng Comm 2007; 9: 65-71.
35. Brittain HG, ed. Polymorphism in Pharmaceutical Solid, Vol. 95. New York: Marcel Dekker, 1999.
36. Grant DJW, Higuchi T,. Solubility Behavior of Organic Compounds. New York: John Willey and Sons, 1990.
37. Zhu H, et al. Influence of water activity in organic solvent + water mixtures on the nature of the crystallizing drug phase. 1. Theophylline. Int J Pharm 1996; 135: 151-160. (Pubitemid 26260884)
38. Zhu H, Grant DJW,. Influence of water activity in organic solvent + water mixtures on the nature of the crystallizing drug phase. 2. Ampicillin. Int J Pharm 1996; 139: 33-43. (Pubitemid 26276265)
39. Qu H, et al. Solubility and stability of anhydrate/hydrate in solvent mixtures. Int J Pharm 2006; 321: 101-107.
40. Qu H, et al. Solvent-mediated phase transformation kinetics of an anhydrate/hydrate system. Cryst Growth Des 2006; 6: 2053-2060.
41. Wikström H, et al. Determination of hydrate transition temperature using transformation kinetics obtained by Raman spectroscopy. J Pharm Biomed Anal 2009; 49: 247-252.
42. Chiarella RA, et al. The nucleation of inosine: the impact of solution chemistry on the appearance of polymorphic and hydrated crystal forms. Faraday Discuss 2007; 136: 179-193.
43. Tian F, et al. Mechanistic insight into the evaporative crystallization of two polymorphs of nitrofurantoin monohydrate. J Cryst Growth 2009; 311: 2580-2589.
44. Luk C-WJ, Rousseau RW,. Solubilities of and transformations between the anhydrous and hydrated forms of L-serine in water-methanol solutions. Cryst Growth Des 2006; 6: 1808-1812.
45. Ostwald WZ,. Studies on formation and transformation of solid materials. Z Phys Chem 1897; 22: 289-330.
46. Qu H, et al. Spectroscopic monitoring of carbamazepine crystallization and phase transformation in ethanol-water solution. Ind Eng Chem Res 2008; 47: 6991-6998.
47. Caillet A, et al. Crystallization of monohydrate citric acid. 1. In situ monitoring through the joint use of Raman spectroscopy and image analysis. Cryst Growth Des 2007; 7: 2080-2087.
48. Nguyen TNP, Kim K-J,. Kinetic study on hemipenta hydrate risedronate monosodium in batch crystallization by cooling mode. Int J Pharm 2008; 364: 1-8.
49. Kim Y, et al. Pseudopolymorphic crystallization of L-ornithine-L- aspartate by drawing out. Ind Eng Chem Res 2003; 42: 883-889.
50. Kitamura M, Hironaka S,. Effect of temperature on antisolvent crystallization and transformation behaviors of thiazole-derivative polymorphs. Cryst Growth Des 2006; 6: 1214-1218.
51. Kitamura M, Nakamura K,. Effect of solvent composition and temperature on polymorphism and crystallization behavior of thiazole-derivative. J Cryst Growth 2002; 236: 676-686. (Pubitemid 34405250)
52. Falcon JA, Berglund KA,. Monitoring of antisolvent addition crystallization with Raman spectroscopy. Cryst Growth Des 2003; 3: 947-952.
53. Kitamura M, Sugimoto M,. Anti-solvent crystallization and transformation of thiazole-derivative polymorphs-I: effects of addition rate and initial concentrations. J Cryst Growth 2003; 257: 177-184.
54. Cardew PT, Davey RJ,. The kinetics of solvent-mediated phase transformations. Proc R Soc Lond 1985; A 398: 415-428.
55. Davey RJ, Cardew PT,. Rate controlling processes in solvent-mediated phase transformations. J Cryst Growth 1986; 79: 648-653.
56. Luhtala S, et al. Effect of benzalkonium chloride on crystal growth and aqueous solubility of carbamazepine. Acta Pharm Fennica 1990; 99: 9-68.
57. Luhtala S,. Effect of poloxamer 184 on crystal growth and aqueous solubility of carbamazepine. Acta Pharm Nord 1992; 4: 172-176.
58. Rodríguez-Hornedo N, Murphy D,. Surfactant-facilitated crystallization of dihydrate carbamazepine during dissolution of anhydrous polymorph. J Pharm Sci 2004; 93: 449-460.
59. Luhtala S,. Effect of sodium lauryl sulphate and polysorbate 80 on crystal growth and aqueous solubility of carbamazepine. Acta Pharma Nord 1992; 4: 85-90.
60. Otsuka M, et al. Effect of binders on polymorphic transformation kinetics of carbamazepine in aqueous solution. Colloids Surf B 2000; 17: 145-152.
61. Mitchell SA, et al. A compaction process to enhance dissolution of poorly water-soluble drugs using hydroxypropyl methylcellulose. Int J Pharm 2003; 250: 3-11.
62. Caillet A, et al. Crystallization of monohydrate citric acid. 2. Modeling through population balance equations. Cryst Growth Des 2007; 7: 2088-2095.
63. Fevotte G, et al. A population balance model of the solution-mediated phase transition of citric acid. AIChE J 2007; 53: 2578-2589.
64. Ono T, et al. Process modeling of the polymorphic transformation of L-glutamic acid. Cryst Growth Des 2004; 6: 1161-1167.
65. Schöll J, et al. In situ monitoring and modeling of the solvent-mediated polymorphic transformation of L-glutamic acid. Cryst Growth Des 2006; 6: 881-891.
66. Haleblian JK, et al. Isolation and characterization of some solid phases of fluprednisolone. J Pharm Sci 1971; 60: 1485-1488.
67. Shefter E, Higuchi T,. Dissolution behavior of crystalline solvated and nonsolvated forms of some pharmaceuticals. J Pharm Sci 1963; 52: 781-791.
68. Khankari RK,. Physicochemical characterization and thermodynamic properties of nedocromil salt hydrates. Minneapolis: University of Minnesota, 1993 (PhD Thesis).
69. Pienaar EW, et al. Polymorphs of nitrofurantoin. I. Preparation and x-ray crystal structures of two monohydrated forms of nitrofurantoin. J Crystall Spectr Res 1993; 23: 739-744.
70. Reutzel-Edens SM, et al. Crystal forms of LY334370 HCl: isolation, solid-state characterization, and physicochemical properties. J Pharm Sci 2003; 92: 1196-1205.
71. Van Tonder EC, et al. Preparation and physicochemical properties of niclosamide anhydrate and two monohydrates. Int J Pharm 2004; 269: 417-432.
72. Caira MR, et al. Polymorphism and pseudopolymorphism of the antibacterial nitrofurantoin. Mol Cryst Liq Cryst Sci Technol Mol Cryst Liq Cryst 1996; 279: 241-264.
73. Otsuka M, Matsuda Y,. Effect of environmental humidity on the transformation pathway of nitrofurantoin modifications during grinding and the physicochemical properties of ground products. J Pharm Pharmacol 1993; 45: 406-413.
74. Kelly RC,. A molecular approach to understanding the directed nucleation and phase transformation of carbamazepine and nitrofurantoin in aqueous and organic solutions. Ann Arbor: University of Michigan, 2003 (PhD Thesis).
75. Aaltonen J, et al. Hyphenated spectroscopy as a polymorph screening tool. J Pharm Biomed Anal 2007; 44: 477-483.
76. Otsuka M, et al. Rotating-disk dissolution kinetics of nitrofurantoin anhydrate and monohydrate at various temperatures. Pharm Res 1992; 9: 307-311.
77. Otsuka M, et al. Characterization of nitrofurantoin anhydrate and monohydrate, and their dissolution behaviors. Chem Pharm Bull 1990; 38: 2667-2670.
78. Wikström H, et al. Towards an understanding of the factors influencing anhydrate-to-hydrate transformation kinetics in aqueous environments. Cryst Growth Des 2008; 8: 2684-2693.
79. Tian F, et al. Crystallization of a polymorphic hydrate system. J Pharm Sci 2010; 99: 753-763.
80. Tian F, et al. Insight into crystallization mechanisms of polymorphic hydrate systems. Chem Eng Technol 2010 33: 833-838.
81. Haynes DA, et al. Occurrence of pharmaceutically acceptable anions and cations in the Cambridge Structural Database. J Pharm Sci 2005; 94: 2111-2120.
82. Gould PL,. Salt selection for basic drugs. Int J Pharm 1986; 33: 201-217.
83. Berge SM, et al. Pharmaceutical salts. J Pharm Sci 1977; 66: 1-19.
84. Serajuddin ATM,. Salt formation to improve drug solubility. Adv Drug Deliv Rev 2007; 59: 603-616.
85. Stahl GP, Wermuth CG, eds. Handbook of Pharmaceutical Salts: Properties, Selection, and Use. Weinheim: Wiley-VCH, 2002.
86. Forbes RT, et al. Physicochemical properties of salts of P-aminosalicylic acid. I. Correlation of crystal structure and hydrate stability. Pharm Res 1992; 9: 1428-1435.
87. Zhu H, et al. Physicochemical characterization of nedocromil bivalent metal salt hydrates. 1. Nedocromil magnesium. J Pharm Sci 1996; 85: 1026-1034.
88. Zhu H, et al. Physicochemical characterization of nedocromil bivalent metal salt hydrates. 2. Nedocromil zinc. J Pharm Sci 1997; 86: 418-428.
89. Guguta C, et al. Structural investigations of hydrate, anhydrate, free base and hydrochloride forms of morphine and naloxone. Cryst Growth Des 2008; 8: 4150-4158.
90. Wu LS, et al. Crystallinity, hygroscopicity and dissolution of moricizine hydrochloride hemihydrate. J Pharm Biomed Anal 1994; 12: 1043-1046.
91. Reutzel SM, et al. Crystal forms of LY334370 HCl: isolation, solid-state characterization, and physicochemical properties. J Pharm Sci 2003; 92: 1196-1205.
92. Bartolomei M, et al. Physico-chemical characterisation and intrinsic dissolution studies of a new hydrate form of diclofenac sodium: comparison with anhydrous form. J Pharm Biomed Anal 2006; 40: 1105-1113.
93. Jørgensen AC, et al. Hydrate formation during wet granulation studied by spectroscopic methods and multivariate analysis. Pharm Res 2002; 19: 1285-1291.
94. Morris KR, et al. Theoretical approaches to physical transformations of active pharmaceutical ingredients during manufacturing processes. Adv Drug Deliv Rev 2001; 48: 91-114.
95. Williams AC, et al. Evaluation of drug physical form during granulation, tabletting and storage. Int J Pharm 2004; 275: 29-39.
96. Bartolomei M, et al. Hydrate modifications of the non-steroidal anti-inflammatory drug diclofenac sodium: solid-state characterisation of a trihydrate form. J Pharm Biomed Anal 2007; 45: 443-449.
97. Bertocchi P, et al. Diclofenac sodium multisource prolonged release tablets-a comparative study on the dissolution profiles. J Pharm Biomed Anal 2005; 37: 679-685.
98. Zimmermann A, et al. Influence of the solid form of siramesine hydrochloride on its behaviour in aqueous environments. Pharm Res 2009; 26: 846-854.